![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways 1Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America 2Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America 3Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America 4Department of Virology, Division of Investigative Science, Faculty of Medicine, Imperial College London, St. Mary's Campus, London, United Kingdom 5Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America Ron A. M. Fouchier, Editor Erasmus Medical Center, The Netherlands * E-mail: branston/at/med.unc.edu Conceived and designed the experiments: MAS LGR KS WSB RJP. Performed the experiments: MAS LGR CS KLR. Analyzed the data: MAS LGR EB RJP. Contributed reagents/materials/analysis tools: KLR WSB. Wrote the paper: MAS WSB RJP. Received October 15, 2008; Accepted April 10, 2009. This article has been cited by other articles in PMC.Abstract Transmission of avian influenza viruses from bird to human is a rare event even though avian influenza viruses infect the ciliated epithelium of human airways in vitro and ex vivo. Using an in vitro model of human ciliated airway epithelium (HAE), we demonstrate that while human and avian influenza viruses efficiently infect at temperatures of the human distal airways (37°C), avian, but not human, influenza viruses are restricted for infection at the cooler temperatures of the human proximal airways (32°C). These data support the hypothesis that avian influenza viruses, ordinarily adapted to the temperature of the avian enteric tract (40°C), rarely infect humans, in part due to differences in host airway regional temperatures. Previously, a critical residue at position 627 in the avian influenza virus polymerase subunit, PB2, was identified as conferring temperature-dependency in mammalian cells. Here, we use reverse genetics to show that avianization of residue 627 attenuates a human virus, but does not account for the different infection between 32°C and 37°C. To determine the mechanism of temperature restriction of avian influenza viruses in HAE at 32°C, we generated recombinant human influenza viruses in either the A/Victoria/3/75 (H3N2) or A/PR/8/34 (H1N1) genetic background that contained avian or avian-like glycoproteins. Two of these viruses, A/Victoria/3/75 with L226Q and S228G mutations in hemagglutinin (HA) and neuraminidase (NA) from A/Chick/Italy/1347/99 and A/PR/8/34 containing the H7 and N1 from A/Chick/Italy/1347/99, exhibited temperature restriction approaching that of wholly avian influenza viruses. These data suggest that influenza viruses bearing avian or avian-like surface glycoproteins have a reduced capacity to establish productive infection at the temperature of the human proximal airways. This temperature restriction may limit zoonotic transmission of avian influenza viruses and suggests that adaptation of avian influenza viruses to efficient infection at 32°C may represent a critical evolutionary step enabling human-to-human transmission. Author Summary Influenza type A viruses are endemic in aquatic birds but can cross the species barrier to infect the human respiratory tract. While transmission from birds to humans is rare, the introduction of novel avian influenza viruses into immunologically naïve human populations has significant pandemic potential. Avian influenza viruses are adapted for growth at 40°C, the temperature of the avian enteric tract. However, the human proximal airways, the likely site of initial inoculation by influenza viruses, are maintained at a cooler temperature (32°C), suggesting that zoonotic transmission may be limited by temperature differences between the two hosts. Using an in vitro model of human ciliated airway epithelium, we show that avian influenza viruses grow well at 37°C, a temperature reflective of distal airways, but are restricted for infection at 32°C. A panel of genetically manipulated human influenza viruses possessing avian or avian-like surface glycoproteins were also restricted at 32°C, but not 37°C, suggesting that avian virus glycoproteins are not adapted for efficient infection at the temperature of the proximal airways. Thus, avian influenza virus infection is restricted in the human proximal airways due to the cooler temperature of this region, thus limiting the likelihood of zoonotic and subsequent human-to-human transmission of these viruses. Introduction Influenza viruses circulating in the human population are predominately type A and B, with type A being more common [1]. All influenza type A viruses originate from aquatic birds and successful introduction of these avian viruses into the human population, by either direct adaptation or reassortment with already circulating human viruses, has led to influenza pandemics of historical significance (reviewed in [2]–[4],[5]). Still, documented evidence of transmission of avian influenza viruses directly from birds to humans is rare, partly because species barriers restrict avian influenza virus infection of the epithelial cells of the human respiratory tract, the primary site of influenza virus infection and spread. Influenza A viruses possess a hemagglutinin (HA) attachment protein that binds sialic acid residues to facilitate infection of target epithelial cells. The HA of human influenza viruses preferentially binds to terminal sialic acid (SA) residues with α2,6 linkages, whereas avian influenza viruses preferentially bind to SA with α2,3 linkages [6]–[9]. The prevalence of α2,6 SA but paucity of α2,3 SA in the human respiratory tract has been considered to restrict infection by avian influenza viruses [10]. Recent reports, however, have detected significant levels of α2,3 SA on human airway epithelium both in vitro and ex vivo, including in nasopharyngeal and tracheobronchial tissue [11]–[14]. This SA distribution also correlated with avian influenza virus infection in vitro and ex vivo and raised the possibility that avian viruses could infect the upper airways in vivo. Therefore, although it is universally accepted that human-to-human transmission of avian influenza viruses requires adaptation of HA to switch from α2,3 to α2,6 SA usage, the cumulative data published to date indicate that SA linkages and their respective distribution in the human airways are not the sole barrier to avian influenza virus infection [15]–[17]. Other host factors and viral genes are likely also important determinants of infectivity. One such host factor that may limit zoonotic transmission is the difference in host temperatures between avian and human tissues that are susceptible to influenza virus infection. Avian influenza viruses are adapted for replication in the avian enteric tract at 40–41°C. While the surface temperatures of the human respiratory tract are variable, a temperature gradient clearly exists in which the surface temperature of the proximal large airways (i.e., nasal and tracheal) average 32+/−0.05°C while temperatures of the smaller, distal airways (i.e., bronchioles) are closer to that of the core body temperature, 37°C [18],[19]. While multiple transmission routes have been described for influenza viruses, the proximal airways likely represent a predominant site for human influenza virus inoculation as they provide a large exposed surface area of virus-susceptible epithelial cells [20]. These cells are directly accessible by large droplet aerosols and by way of digital inoculation of the nasopharynx and conjunctival mucosa [12],[21]. Inefficient infection by avian influenza viruses, even in the presence of α2,3-linked SA, may be due to the cooler temperature of the proximal airways compared to that of the distal airways/lung regions where H5N1 avian influenza viruses appear to replicate efficiently [22]. Avian influenza viruses are attenuated at temperatures below 37°C and cold sensitivity of avian viral RNA replication in cell lines was linked to the presence of a glutamic acid at amino acid 627 in the avian virus polymerase subunit, PB2, instead of a lysine in the human virus PB2 [23]. Lysine substitution at residue 627 of H5N1 viruses improved virus replication in mice [24]. In addition to PB2, work utilizing human-avian reassortant viruses in MDCK cells provided initial evidence that avian glycoproteins, HA and neuraminidase (NA), may mediate temperature-dependent effects on viral growth [25]. To our knowledge, other viral genes have not been well characterized, nor the HA and NA further evaluated, in their contribution to temperature sensitivity of avian influenza viruses. To characterize the temperature dependency of avian vs. human influenza viruses in a relevant model of the target cell types of the human airways, we utilized an in vitro model of human ciliated airway epithelium (HAE). This model closely mimics the morphological and physiological features of the human airway epithelium in vivo and has been previously used to investigate infection by diverse respiratory viruses [26]–[30]. In humans, ciliated airway epithelium is present throughout the airways, extending from the nasal cavity and large proximal airways into the distal bronchiolar airway regions. Previously, we have shown that both human and avian influenza viruses replicate well in HAE and that human and avian influenza virus cell tropism correlates with the respective distribution of the specific sialic acid linkages [13]. However, these previous studies were conducted at 37°C, reflecting conditions encountered in the distal airways [13]. Others have also utilized these airway cell systems to characterize influenza virus replication of wild-type and recombinant viruses at 35°C [14],[31],[32]. In the present study, we utilize the HAE model, in combination with influenza virus reverse genetics, to investigate the influence of temperature on human and avian influenza virus infection, replication and spread. We demonstrate that, compared to human influenza viruses, avian influenza viruses are severely restricted for infection of human airway epithelium at the temperature of the human proximal airways. Then, using different strategies to ‘avianize’ human influenza viruses, we show that the temperature restriction of avian viruses is closely associated with the avian HA and NA glycoproteins. Results Human and avian influenza virus infection of human ciliated airway epithelium at 32°C and 37°C We and others have previously shown that human and avian influenza viruses infect and replicate in HAE [13],[14],[31]. Since our previous experiments were performed at 37°C, a temperature reflective of human distal airways, we have now compared human and avian influenza virus infection and growth in HAE at temperatures reflective of the proximal airways (32–33°C) and distal airways (37°C). HAE were inoculated at either 32°C or 37°C with a low multiplicity of infection (MOI; 0.01) of a representative human virus, A/Victoria/3/75 (H3N2), or an avian influenza isolate, A/Dk/Eng/62 (H4N6). Virus growth and spread throughout the epithelium at the two temperatures was measured and compared over time and infection further characterized with respect to virus-induced cytopathic effects (CPE). At the temperature of the distal airways (37°C), the growth kinetics and mean peak titers of A/Victoria/3/75 and A/Dk/Eng/62 reached 2.3×108 pfu/ml and 4.7×107 pfu/ml, respectively, by 48 hours post-inoculation (hrs pi) (Figure 1A
In comparison to 48 hr titers, A/Victoria/3/75 titers at both temperatures and A/Dk/Eng/62 titers at 37°C were reduced at 72 hr pi and every time point thereafter, indicating reduced progeny virus production. A loss of titer was also observed for A/Dk/Eng/62 at 32°C, but not before 120 hrs pi. To determine if loss of titer after reaching maximum levels correlated with increased CPE, we quantified adenylate kinase (AK) release by dead/dying cells into the apical compartment as a sensitive and global measure of cytotoxicity across the entire epithelial cell culture surface. Figure 1B A relationship between the kinetics of virus growth in HAE and the level of CPE also suggested that CPE was a consequence of viral replication. This assertion is supported by the fact that trends in viral titers at a given time point are mirrored in AK levels detected 48 hrs later (e.g., compare viral titers at 48 hr pi (Figure 1A
In contrast to A/Victoria/3/75, A/Dk/Eng/62 antigen was detected in only a few cells 24 hrs pi at either temperature. However, it should be noted that antigen-positive cells in en face images are viewed linearly (Figure 2A HAE cultures infected with A/Victoria/3/75 at either 32°C or 37°C and A/Dk/Eng/62 at 37°C viewed en face exhibited loss of integrity of the epithelium although the extent of injury and time of onset varied (Figure 2A In sum, for both viruses at both temperatures, detection of maximal numbers of antigen-positive cells correlated with high titers (compare Figure 1A Avian influenza virus restriction at 32°C is independent of avian virus strain To determine whether other avian, but not human, influenza viruses display temperature dependent phenotypes, we performed multi-step growth curves with more human H3N2 isolates (A/Eng/26/99 and A/Udorn/307/72) and A/Dk/Sing/97, an avian isolate of different subtype (H5N3). Growth of both human-derived influenza viruses tested, A/Eng/26/99 (H3N2) and A/Udorn/307/72 (H3N2), was not significantly different between 32/33°C and 37°C (Figure 3A and 3B
Assessment of growth of avian influenza virus, A/Dk/Sing/97 (H5N3), over a 48 hr time course at 37°C showed similar growth kinetics to that of A/Eng/26/99 (H3N2), reaching titers of 7×105 pfu/ml and 1.6×106 pfu/ml, respectively (Figure 3A and 3C Since the avian virus isolates used in these experiments are neither derived from samples obtained from humans nor passaged in human cells in vitro, we next investigated whether growth attenuation at low temperatures would be retained in a highly pathogenic H5N1 (A/VN/1203/04) influenza virus isolated from a fatal human case [34]. We compared infection kinetics of H5N1 (A/VN/1203/04) at 33°C and 37°C on HAE using A/Udorn/307/72 in parallel cultures as a human influenza virus control. As described above, A/Udorn/307/72 grew with similar kinetics at 33°C and 37°C (Figure 3B ‘Avianization’ of human virus polymerase restricts growth in HAE at both 32°C and 37°C Previously, the polymerase subunit PB2 has been shown to play an important role in host range restriction of avian influenza viruses in mammalian cells [37]–[39]. In influenza virus strains that circulate in humans, amino acid residue 627 in PB2 is a lysine, whereas in the majority of avian strains it is a conserved glutamic acid residue. The presence of glutamic acid at PB2 627 (avian-like) has been reported to account for the lower replication of avian influenza strains in mammalian cells and has been linked with reduced polymerase activity at lower temperature (33°C) in some cell systems [23],[24]. To assess the potential impact of this PB2 amino acid residue in restriction of avian influenza viruses at 32°C, we generated a recombinant A/Victoria/3/75 virus containing the PB2 K627E mutation and compared its growth with that of the isogenic wild-type virus in HAE at 32°C and 37°C. The K627E mutation resulted in restriction of the virus at both temperatures (Figure 4Ai
Human influenza viruses with avian-like glycoproteins display restricted replication and spread at 32°C in HAE Our initial phenotype indicated that A/Dk/Eng/62 was restricted in its ability to spread from cell to cell within the epithelium at 32°C (Figure 2A We again compared virus replication and spread of the recombinant viruses to that of wild-type A/Victoria/3/75 at the two temperatures. As stated above, replication measured for the wild-type virus was slightly compromised at lower temperature, noticeable at 24 hrs pi. Restriction at this time point was also observed during infection of HAE with Vic-226-228HA, as it had been for the PB2 mutant virus. Specifically, a 2.5 log decrease in virus growth was determined for Vic-226-228HA at 32°C compared to 37°C at the 24 hr time point (Figure 4Bi Similarly, the reassorted virus Vic+Chick N1 displayed a 2 log decrease in viral titer in HAE at 32°C compared to 37°C at 24 hrs pi. Although this difference was not appreciably greater than the difference in titer between temperatures for either wild-type virus or the PB2 mutant, Vic+Chick N1, unlike wild-type A/Victoria/3/75 and Vic 627PB2, maintained the ~2-log difference in growth at 48 hrs pi (Figure 4Ci We next generated a recombinant influenza virus containing both the 226-228HA and Chick N1 and tested infection and growth in HAE at 32°C and 37°C in comparison to wild-type A/Victoria/3/75. At 24 hrs pi, the double glycoprotein-altered virus exhibited similar restriction as observed for the other viruses. Nonetheless, an overall evaluation of the double glycoprotein-altered virus suggested that as infection proceeded, this virus was profoundly restricted at 32°C compared to 37°C (Figure 4Di Determination of CPE during these experiments revealed that the double glycoprotein-avianized virus only produced CPE at 72 hrs pi when experiments were performed at 37°C, whereas wild-type human virus produced CPE earlier and at both temperatures (data not shown). These data are consistent with the levels of CPE observed for A/Dk/Eng/62 (H4N6) and A/Victoria/3/75 (H3N2) in our initial studies (Figure 1B Avian influenza virus glycoproteins dictate cell tropism and restrict growth of virus in HAE at 32°C One potential caveat of the recombinant viruses with avianized HA and/or NA utilized in our previous analysis was that they contained HA and NA pairs that had not co-evolved. To eliminate the possibility that the restriction we observed with these recombinant viruses was due to an imbalance between the activities of the surface glycoproteins that were not evolutionarily optimized, we next generated reassorted influenza viruses on a common genetic background, possessing human or avian glycoproteins with co-evolved pairings. This was achieved using human recombinant A/PR/8/34 (H1N1) in which the wild-type H1 and N1 glycoproteins were replaced by the H3 and N2 glycoprotein pair from A/Victoria/3/75 (generating PR8+Vic HA/NA) or the H7 and N1 glycoprotein pair from A/Chick/Italy/1347/99 (generating PR8+Chick HA/NA, previously termed RD3) [41]. Since we and others have shown differential cell-type tropism between human and avian influenza virus in HAE [13],[14], we next determined if avianizing the human virus HA by mutation or substitution (in the presence or absence of an avian NA) recapitulated the cell-type tropism exhibited by wholly avian influenza viruses in HAE. As shown by immunofluorescent detection in histological sections of infected HAE, PR8 containing A/Victoria/3/75 glycoproteins infected both ciliated and non-ciliated cells in HAE with a tropism similar to wild-type A/Victoria/3/75 (Figure 5
Growth kinetics in HAE of PR8+Vic HA/NA and PR8+Chick HA/NA inoculated at equal MOI (0.01) revealed that PR8+Vic HA/NA infection and growth was efficient at both 32°C and 37°C (Figure 6A
As observed for wholly human and avian influenza viruses, peak titers were reached for PR8+Vic HA/NA at both temperatures and PR8+Chick HA/NA at 37°C by 48 hrs pi after which a decline in viral titer was apparent. Again, as noted in our observations with human and avian influenza viruses, the loss of viral titers with time correlated with the onset of CPE. While PR8+Chick HA/NA infection at 32°C did not result in substantial AK release until 96 hr pi, increased AK activity was detected in cultures inoculated with this virus at 37°C. AK activity measured in cultures at this temperature increased with similar kinetics and reached similar levels as AK measured in cultures inoculated with PR8+Vic HA/NA at either temperature. Furthermore, the kinetics of AK induction demonstrated that again, AK was consequential to viral replication and that, overall, CPE induced by reassortant viruses was reflective of CPE measured for human and avian influenza viruses. En face staining of HAE at 24 hr intervals after inoculation showed PR8+Chick HA/NA spread to additional target cells at 37°C at a rate similar to that of PR8+Vic HA/NA at 32°C and correlated with the titers measured for these two viruses under those conditions (Figure 6C and 6D Discussion We have performed comparative studies of the infection kinetics of human and avian influenza viruses in a model of human ciliated airway epithelium at temperatures reflective of the human proximal and distal airways. Our data show that avian and avianized influenza viruses are restricted for infection and growth in HAE at 32°C but not 37°C, while human viruses infect and grow efficiently at both temperatures. Based on these data, we suggest that while the warmer temperatures of the distal airways enable comparable infection by both human and avian influenza viruses, the cooler temperatures of the human proximal airways only support efficient and robust infection of the ciliated airway epithelium by human influenza viruses. We speculate that the observed restriction for avian and ‘avianized’ viruses in HAE would render avian influenza viruses more susceptible to innate and adaptive immune responses that limit pathogenicity in vivo. These results have significant impact on our understanding of why avian influenza viruses rarely undergo zoonotic transmission and why, when the rare human case does occur, that avian influenza virus infection and pathology manifest predominately in the warmer distal airways and lungs. The inability of avian influenza viruses to replicate efficiently at cooler temperatures has been linked to the viral polymerase subunit, PB2 [23],[24]. In the present study, mutating position 627 in a human virus PB2 to an avian virus conserved residue resulted in growth restriction at both 32°C and 37°C, suggesting that this residue is important for general viral fitness in HAE, but is not responsible for the differences in infection seen at 32°C vs. 37°C. Two recent reports also found that viruses with 627E in PB2 were attenuated regardless of temperature in human bronchial epithelial cells and MDCK cells, respectively, although in other cell systems including human small airway epithelial cells, a temperature specific effect was found [24],[42]. It should be emphasized that those studies were performed in non-differentiated epithelial cells unlike our studies that use human differentiated airway epithelial cells. We and others have previously shown that differentiated airway epithelial cell models enable discrimination of attenuated phenotypes of respiratory virus infection whereas non-differentiated cells do not [26],[27],[43]. In addition, we also show using HAE, that the H5N1 strain A/VN/1203/04, which possesses a lysine at position 627 (human adaptation), is still restricted for growth at 32°C, albeit less so than avian influenza viruses that have never infected humans. The attenuation in HAE of this H5N1 isolate which possesses a “human” amino acid at residue 627 in PB2 suggests other residues in the polymerase subunit or other viral proteins altogether are involved in temperature sensitivity of avian influenza viruses. In our initial experiments, spread of avian influenza viruses from cell to cell at 32°C was compromised in cultures inoculated at low MOI, suggesting a potential role for the envelope glycoproteins, HA and NA, in mediating temperature restriction. Previous work by Kaverin and colleagues also demonstrated temperature effects on growth of human-avian reassortant viruses containing avian glycoproteins [25], although this work was performed in non-polarized MDCK cells and did not investigate additional correlates of infection such as spread and CPE. In our study, we generated recombinant influenza viruses based on the A/Victoria/3/75 or A/PR/8/34 genetic backbone that were engineered to contain avian-like and/or avian glycoproteins and characterized infection in HAE. Kinetic studies showed that although human influenza viruses that possessed avian or avian-like surface glycoproteins were modestly restricted compared to wild-type viruses at 37°C, these mutant viruses were able spread like wild-type viruses throughout HAE at this temperature. Wide-spread infection throughout HAE was even observed for viruses in which their endogenous HA was replaced or mutated to preferentially bind α2,3 SA, restricting tropism to ciliated cells. Efficient replication of Vic-226-228HA at 37°C in our studies corroborates previous work by Matrosovich and colleagues in which little effect of HA-specificity ‘switching’ on replication was noted unless a very low MOI (0.00004) was used for inoculation [44]. In contrast, Wan and Perez described more profound differences in replication in HAE at 37°C with recombinant viruses that differed only in their receptor specificity [31]. However, it should be noted that their recombinant viruses were based on an H9N2 avian strain that yielded relatively low titers, and their initial infections were performed at 35°C before incubating at 37°C [31]. Compared to 37°C, viruses with a preference for binding to α2,3 SA, including Vic-226-228HA, were restricted for growth and spread in HAE at 32°C. Notably, the H5N1 strain examined in this study also maintains preference for α2,3 SA binding [45]; thus, we may surmise that this characteristic of A/VN/1203/04 contributes to its attenuation observed in HAE. The contribution of α2,3 SA usage to replication of influenza viruses investigated by Hatta et al. in the upper respiratory tract of mice may have been masked in the mouse model (the 627 mutation in PB2 being more apparent) as mice express solely avian virus-like receptors (α2,3 SA) in their airways [46]. Restriction of α2,3 SA-binding viruses in HAE at 32°C was not due to a discrepancy in SA expression since HAE maintained at either 32°C or 37°C expressed similar levels of α2,6 and α2,3 SA (as detected by Sambucus nigra (SNA) and Maackia amurensis (MAA) lectin staining, respectively; data not shown). In conjunction with the HA, the sialidase activity of NA is crucial for successful virus penetration of mucus layers for initial infection and subsequent release of progeny virions from infected cells [47],[48]. This is especially critical both in vivo and in HAE models in which the luminal epithelial cell surface is robust with glycoconjugates displaying abundant terminal sialic acid moieties that may act as false receptors for influenza viruses [49]. Using standard laboratory assays that employ small monovalent soluble substrates for cleavage by NA (MUNANA), we were not able to demonstrate any temperature-dependent loss of NA activity associated with either human or avian virus (data not shown). However, the ability of the avian virus NA to cleave biologically relevant substrates present in HAE may be compromised at 32°C vs. 37°C restricting both initial infection and subsequent spread of the virus throughout the epithelium. This is supported by our data which demonstrate restricted growth and spread of reassortant viruses containing avian virus NA, including Vic+Chick N1 and PR8+Chick HA/NA in HAE at 32°C. In addition to their independent functions, the balance between the binding affinity of the viral HA and the sialidase activity of the NA is also critical for efficient infection. The ability of A/Victoria/3/75 viruses with mutations or substitutions in either the HA or NA alone to infect similar numbers of cells and replicate to comparable peak titers as for wild-type virus at 37°C implies that these viruses were not crippled by the mismatch between the specificities of their HA and NA. Replication and spread of influenza viruses that possess an avian HA paired with its “matched” NA was even more compromised than that of recombinant viruses with individual changes to levels seen with wholly avian viruses. Thus, viruses with co-evolved glycoprotein pairs exhibit restricted replication at low temperatures and both HA and NA genes contribute to the phenotype. Together, these data imply that in the complex environment of the luminal surface of the human ciliated airway epithelium, the viral surface antigens have a marked effect on the extent of virus infection and that temperature plays an important role in limiting avian, but not human, influenza virus infection and spread in the cooler proximal airway regions. Given these results, we draw attention to other recently published data using the HAE model in which mutations in viruses that are growth attenuated in vivo display similar growth attenuation in HAE but not in non-differentiated cell lines, suggesting that HAE possess discriminating properties of attenuating phenotypes of mutants of respiratory viruses [26],[27]. Admittedly, in the present study, despite restriction in both growth and spread, wild-type avian viruses and human viruses with avian or avian-like glycoproteins did eventually reach high titer at 32°C at later time points. The efficiency of infection and replication of a virus that inoculates the airway epithelium, however, is likely a critical factor in determining whether the virus is capable of establishing infection in a host that normally possesses innate and adaptive immune systems that attempt to limit virus infection and spread. At temperatures of the distal airways, avian influenza viruses displayed similar infection kinetics as human influenza viruses and would therefore, in the case of sufficient inoculum reaching these distal regions, be as likely to establish infection. Indeed, the clinical pathology findings for humans infected with H5N1 do report distal airway infection in ciliated bronchioles and lung regions [22]. Under these conditions of inoculation and infection, avian influenza viruses present in the distal airways may still be unable to spread to proximal airway regions without additional adaptation to cooler temperatures. One caveat of this prediction is that virus may be transported to proximal airway regions by innate mucus clearance mechanisms indicating that caution is required when attempting to identify proximal infection by viruses in airway secretions obtained from tracheal swabs. In conclusion, the present study substantiates differential host temperature as a critical barrier for infection by avian influenza viruses. Since the ciliated airway epithelium of the proximal airways is a major portal for influenza virus infection and spread, accessible by multiple inoculation routes (e.g., ocular, nasopharyngeal or aerosol), the inability of avian influenza viruses to establish infection and spread in these regions would be predicted to reduce the frequency of successful zoonotic transmission. Furthermore, the ability of human influenza viruses to generate high viral titers in the human proximal airways is likely a factor in effective human-to-human transmission and the induction of airway epithelial cell cytotoxicity as shown in this study may increase particulate matter perhaps associated with virus that facilitates inoculation of new hosts. Rapid induction of cytotopathic effects by human, but not avian, influenza virus infection at the temperature of the human proximal airways may also contribute to the onset of other host defenses such as sneezing and coughing that facilitate clearance of particulate matter/virus from the airways and potentially promote transmission between human hosts. Materials and Methods Cells Human airway tracheobronchial epithelial cells isolated from airway specimens from patients without underlying lung disease were provided by the National Disease Research Interchange (NDRI, Philadelphia, PA) or as excess tissue following lung transplantation under University of North Carolina at Chapel Hill (UNC) Institutional Review Board-approved protocols by the UNC Cystic Fibrosis Center Tissue Culture Core. Primary cells derived from single patient sources were expanded on plastic to generate passage 1 cells and plated at a density of 3×105 cells per well on permeable Transwell-Col (12-mm diameter) supports (Corning, Inc.). HAE cultures were grown in custom media with provision of an air-liquid interface for 4 to 6 weeks to form differentiated, polarized cultures that resemble in vivo pseudostratified mucociliary epithelium, as previously described [50]. Madin-Darby Canine Kidney (MDCK) cells were maintained in DMEM (Gibco-Invitrogen, Inc.) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin (Sigma-Aldrich, Inc.). Viruses Influenza virus A/England/26/99 (H3N2) was isolated at the Health Protection Agency, Colindale, London, UK, during the routine surveillance program and has been minimally passaged in MDCK cells [51]. A/Dk/Singapore/97 (H5N3) and A/Dk/England/62 (H4N6) are typical avian influenza strains that have been passaged in both embryonated chicken eggs and MDCK cells during laboratory handling. Highly pathogenic A/VN/1203/04 (H5N1) was biologically derived and minimally passaged in embryonated chicken eggs. A/Udorn/307/72 (H3N2) was passed in baby hamster kidney (BHK) cells and represents a clone expanded once in embryonated chicken eggs. Recombinant viruses, including wild-type A/Victoria/3/75 (H3N2) and mutants in either the A/Victoria/3/75 (H3N2) or A/PR/8/24 (H1N1) background, were generated from cloned cDNA in 293T and MDCK cell co-cultures as previously described [52],[53]. Mutant viruses were generated in either the A/Victoria/3/75 (H3N2) or A/PR/8/34 (H1N1) genetic background as follows: 1) Vic 627PB2; A/Victoria/3/75 containing a lysine to glutamic acid amino acid substitution at position 627; 2) Vic-226-228HA; A/Victoria/3/75 containing two amino acid substitutions in the HA gene (L226Q, S228G) that confer an avian-like receptor binding preference [6],[40]; 3) Vic+Chick N1; A/Victoria/3/75 in which segment 6 containing the endogenous N2 NA gene was exchanged for the N1 NA gene from avian isolate A/Chick/Italy/1347/99; 4) Vic-226-228HA+Chick N1; A/Victoria/3/75 containing both L226Q and S228G mutations and the avian N1; 5) PR8+Vic HA/NA; A/PR/8/34 in which the endogenous H1 and N1 were replaced with the H3 and N2 from A/Victoria/3/75 and 6) PR8+Chick HA/NA (RD3); A/PR/8/34 in which the endogenous H1 and N1 were replaced with the H7 and N1 from A/Chick/Italy/1347/99. (RD3 was previously described as a candidate vaccine strain [41].) The last two reassortant viruses were generated by substituting segment 4 and segment 6 from PR8 with those from either A/Victoria/3/75 (H3N2) or A/Chick/Italy/1347/99 (H7N1). The multi-basic cleavage site in the avian H7 HA gene used in these studies was removed prior to rescue of these recombinant viruses for safety. Available accession numbers (GenBank: http://www.ncbi.nlm.nih.gov.libproxy.lib.unc.edu) are V01086 for A/Victoria/3/75 HA and CAD37074 for A/Chick/Italy/1347/99 HA. Viral inoculation and growth in HAE HAE were rinsed with PBS to transiently remove apical secretions and supplied with fresh basolateral medium prior to inoculation. Virus inoculum was diluted in PBS and applied to the apical surface of HAE for 2 hrs at either 32°C, 33°C, or 37°C, as indicated. Following incubation, viral inocula were removed and cultures incubated at 32°C, 33°C or 37°C for the duration of the experiment. Viral growth kinetics were determined by performing apical washes with 300 µl of serum-free DMEM for 30 min at either 32°C or 37°C. Washes were harvested and stored at −80°C prior to analysis. Viral titers in the apical washes were determined by standard plaque assay or tissue culture infectious dose (TCID)50 assay on MDCK cell monolayers as previously described [13],[52],[54]. En face staining At various points post-inoculation (pi), HAE were fixed in cold methanol-acetone (50/50) and stored at 4°C. Cultures were then permeabilized with 2.5% triton-X 100/PBS++ (containing 1 mM CaCl2 and 1 mM MgCl2) and blocked with 3% bovine serum albumin (BSA) in PBS++ before being probed with mouse anti-influenza virus nucleoprotein (NP; Chemicon, Inc.; 1 100) and immunoreactivity detected with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories, Inc., 1 500). Fluorescent images were obtained using a Leica DMIRB inverted fluorescence microscope equipped with cooled-color charge-coupled-device digital camera (MicroPublisher; Q-Imaging, Burnaby, BC, Canada). The percentage of the epithelium positive for viral antigen as an index of percentage of infected cells was quantified over 5 images per culture by black and white pixilation of each image and computer calculation of percent black pixels after inverting the image. This technique determines percentage of black pixels in a defined area and does not account for differences in fluorescent intensity.Measures of CPE Viral-induced cytotoxicity was determined by measuring adenylate kinase activity in apical washes using a commercially available assay (Lonza, Inc.). Apical samples were centrifuged prior to freezing to remove any cellular contaminants present in the wash. Luminescence detected in samples from infected HAE were normalized to uninfected HAE and expressed as fold change over AK measured in uninfected (mock) HAE. Morphological assessment of cytotoxicity in HAE was performed with paraformaldehyde (PFA, 4%)-fixed histological sections (5 µm) stained with hematoxylin and eosin. Detection of α2,3 and α2,6 linked sialic acids HAE maintained at either 32°C or 37°C for 72 hrs prior to sialic acid detection were washed, blocked with 3% BSA/PBS++ and probed with biotinylated SNA or MAA lectins to detect α2,6 and α2,3 SA, respectively (Vector Laboratories, Inc.; EY-Laboratories, Inc.; 1 100). HAE were then fixed in 4% PFA and incubated with streptavidin-alexafluor 488 (Molecular Probes, Inc.; 1 500) applied to the apical surface to detect lectin binding.Immunohistochemistry HAE fixed in methanol acetone, were probed en face with antibody against viral NP (Chemicon, Inc.; 1 100) and FITC-conjugated goat anti-mouse IgG1 and IgG2a (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA; 1 500), then embedded in paraffin. Histological sections (5 µm) were prepared and reprobed for viral antigen using standard immunofluorescence protocols. Briefly, sections were bathed in 2.5% triton-X 100/PBS++ for 30 min, blocked in 3% BSA/PBS++ and incubated with antibodies in 1% BSA/PBS++. Primary antibodies were anti-viral NP (Chemicon, Inc., as above) and anti-alpha acetylated tubulin (Zymed Laboratories, Inc.; 1 2000), a marker for ciliated cells. Secondary antibodies were FITC-goat anti-mouse IgG2a and Rhodamine red-conjugated goat-anti-mouse IgG2b (Jackson ImmunoResearch Laboratories, Inc.; 1 500). Sections were prepared with FluorSave mounting media (EMD Chemicals, Inc.) and images captured using a Leica DMIRB inverted fluorescence microscope equipped with a cooled color charge-coupled-device digital camera (MicroPublisher; Q-Imaging, Burnaby, British Columbia, Canada).Statistical analysis Linear mixed models were fitted to the repeated measurements of log-transformed viral titer over time that included effects for the four treatment groups (defined by virus and temperature), eight time points, and the interaction between treatment and time. We note that in a small number of cases, there were only two treatment groups (defined by temperature) and fewer than eight time points. A heterogeneous autoregressive correlation structure of order one was assumed for the repeated measurements. A joint test of the interaction terms (21 degrees of freedom) provides an assessment of the hypothesis of no differences among the four treatment groups with respect to viral titer growth (log scale). Provided this test was significant, indicating some differences among the four growth curves, pair-wise differences between the three treatment groups versus the a priori specified reference group (generally the avian strain at the lowest temperature) were carried out for each time point, and significant differences at the 0.05 level were noted. No adjustments for inflated Type I error due to multiple comparisons were made. Missing observations were assumed to be missing completely at random, based on the fact that the investigators determined a priori to remove samples at specific time points during the experiment. Acknowledgments We are grateful to the directors and teams of the UNC Cystic Fibrosis Center Core Facilities (Tissue Culture Core, Morphology and Morphometry Core, and the Michael Hooker Microscopy Facility) for supplying reagents and technical expertise, and to Susan Burkett for technical assistance. Footnotes The authors have declared that no competing interests exist. This work was supported by the National Institutes of Health (NIH) Molecular Biology of Viral Diseases Training Grant 5-T32-AI007419, NIH R01 HL77844-1, NIH R21 HL080098-01, SCCOR 5 P50 HL084934, and MRC G0600504. MAS (nee Hennessey) is a recipient of the George H. Hitchings Fund for Health Research and Science Education of the Triangle Community Foundation. WSB is a member of the Wellcome Trust-funded Centre for Respiratory Infection Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. References 1. Prevention CfDCa. Update: Influenza Activity-United States, September 30, 2007–February 9, 2008. MMWR. 2008;57:179–183. [PubMed] 2. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56:152–179. [PubMed] 3. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591–600. [PubMed] 4. Reid AH, Taubenberger JK, Fanning TG. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol. 2004;2:909–914. [PubMed] 5. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology. 1978;87:13–20. [PubMed] 6. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology. 1994;205:17–23. [PubMed] 7. Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, et al. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6′-sialyl(N-acetyllactosamine). Virology. 1997;232:345–350. [PubMed] 8. Matrosovich MN, Gambaryan AS, Teneberg S, Piskarev VE, Yamnikova SS, et al. Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology. 1997;233:224–234. [PubMed] 9. Rogers GN, Paulson JC. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127:361–373. [PubMed] 10. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. Avian flu: influenza virus receptors in the human airway. Nature. 2006;440:435–436. [PubMed] 11. Nicholls JM, Bourne AJ, Chen H, Guan Y, Peiris JS. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res. 2007;8:73. [PubMed] 12. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med. 2007;13:147–149. [PubMed] 13. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol. 2006;80:8060–8068. [PubMed] 14. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A. 2004;101:4620–4624. [PubMed] 15. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol. 1999;73:1146–1155. [PubMed] 16. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006;312:404–410. [PubMed] 17. Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science. 2007;315:655–659. [PubMed] 18. McFadden ER, Jr, Pichurko BM, Bowman HF, Ingenito E, Burns S, et al. Thermal mapping of the airways in humans. J Appl Physiol. 1985;58:564–570. [PubMed] 19. Lindemann J, Leiacker R, Rettinger G, Keck T. Nasal mucosal temperature during respiration. Clin Otolaryngol Allied Sci. 2002;27:135–139. [PubMed] 20. Hayden F, Croisier A. Transmission of avian influenza viruses to and between humans. J Infect Dis. 2005;192:1311–1314. [PubMed] 21. Bitko V, Musiyenko A, Barik S. Viral infection of the lungs through the eye. J Virol. 2007;81:783–790. [PubMed] 22. Uiprasertkul M, Puthavathana P, Sangsiriwut K, Pooruk P, Srisook K, et al. Influenza A H5N1 replication sites in humans. Emerg Infect Dis. 2005;11:1036–1041. [PubMed] 23. Massin P, van der Werf S, Naffakh N. Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. J Virol. 2001;75:5398–5404. [PubMed] 24. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, et al. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog. 2007;3:1374–1379. doi:10.1371/journal.ppat.0030133. [PubMed] 25. Kaverin NV, Rudneva IA, Smirnov YA, Finskaya NN. Human-avian influenza virus reassortants: effect of reassortment pattern on multi-cycle reproduction in MDCK cells. Arch Virol. 1988;103:117–126. [PubMed] 26. Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, et al. The role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J Virol. 2008;82:8059–8070. [PubMed] 27. Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, et al. Human parainfluenza virus type 1 C proteins are non-essential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in non-human primates. J Virol. 2008;82:8965–8977. [PubMed] 28. Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol. 2005;79:1113–1124. [PubMed] 29. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002;76:5654–5666. [PubMed] 30. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79:15511–15524. [PubMed] 31. Wan H, Perez DR. Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. J Virol. 2007;81:5181–5191. [PubMed] 32. Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 2008;4:e1000072. doi:10.1371/journal.ppat.1000072. [PubMed] 33. Hers JF. Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis. 1966;93(Suppl):162–177. [PubMed] 34. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol. 2005;79:11788–11800. [PubMed] 35. Lam WY, Tang JW, Yeung AC, Chiu LC, Sung JJ, et al. Avian influenza virus A/HK/483/97(H5N1) NS1 protein induces apoptosis in human airway epithelial cells. J Virol. 2008;82:2741–2751. [PubMed] 36. Daidoji T, Koma T, Du A, Yang CS, Ueda M, et al. H5N1 avian influenza virus induces apoptotic cell death in mammalian airway epithelial cells. J Virol. 2008;82:11294–11307. [PubMed] 37. Almond JW. A single gene determines the host range of influenza virus. Nature. 1977;270:617–618. [PubMed] 38. Subbarao EK, London W, Murphy BR. A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol. 1993;67:1761–1764. [PubMed] 39. Yao Y, Mingay LJ, McCauley JW, Barclay WS. Sequences in influenza A virus PB2 protein that determine productive infection for an avian influenza virus in mouse and human cell lines. J Virol. 2001;75:5410–5415. [PubMed] 40. Vines A, Wells K, Matrosovich M, Castrucci MR, Ito T, et al. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J Virol. 1998;72:7626–7631. [PubMed] 41. Whiteley AMD, Legastelois I, Campitelle L, Donatelli I, et al. Generation of candidate human influenza vaccine strains in cell culture—rehearsing the European response to an H7N1 pandemic threat. Influenza Resp Viruses. 2007;1:157–166. 42. Steel J, Lowen AC, Mubareka S, Palese P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog. 2009;5:e1000252. doi:10.1371/journal.ppat.1000252. [PubMed] 43. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, et al. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol. 2005;79:8651–8654. [PubMed] 44. Matrosovich M, Matrosovich T, Uhlendorff J, Garten W, Klenk HD. Avian-virus-like receptor specificity of the hemagglutinin impedes influenza virus replication in cultures of human airway epithelium. Virology. 2007;361:384–390. [PubMed] 45. Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, et al. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol. 2007;81:6890–6898. [PubMed] 46. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, et al. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol. 2006;80:7469–7480. [PubMed] 47. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004;78:12665–12667. [PubMed] 48. Gottschalk A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim Biophys Acta. 1957;23:645–646. [PubMed] 49. Stonebraker JR, Wagner D, Lefensty RW, Burns K, Gendler SJ, et al. Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to lumenal infection. J Virol. 2004;78:13755–13768. [PubMed] 50. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, et al. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol. 1998;72:6014–6023. [PubMed] 51. Thompson CI, Barclay WS, Zambon MC. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J Antimicrob Chemother. 2004;53:759–765. [PubMed] 52. Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology. 2004;321:144–153. [PubMed] 53. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999;96:9345–9350. [PubMed] 54. Gaush CR, Smith TF. Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol. 1968;16:588–594. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
MMWR Morb Mortal Wkly Rep. 2008 Feb 22; 57(7):179-83.
[MMWR Morb Mortal Wkly Rep. 2008]Microbiol Rev. 1992 Mar; 56(1):152-79.
[Microbiol Rev. 1992]Nat Rev Microbiol. 2004 Nov; 2(11):909-14.
[Nat Rev Microbiol. 2004]Virology. 1978 Jun 1; 87(1):13-20.
[Virology. 1978]Virology. 1994 Nov 15; 205(1):17-23.
[Virology. 1994]Virology. 1983 Jun; 127(2):361-73.
[Virology. 1983]Nature. 2006 Mar 23; 440(7083):435-6.
[Nature. 2006]Respir Res. 2007 Oct 25; 8():73.
[Respir Res. 2007]Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4620-4.
[Proc Natl Acad Sci U S A. 2004]J Appl Physiol. 1985 Feb; 58(2):564-70.
[J Appl Physiol. 1985]Clin Otolaryngol Allied Sci. 2002 Jun; 27(3):135-9.
[Clin Otolaryngol Allied Sci. 2002]J Infect Dis. 2005 Oct 15; 192(8):1311-4.
[J Infect Dis. 2005]Nat Med. 2007 Feb; 13(2):147-9.
[Nat Med. 2007]J Virol. 2007 Jan; 81(2):783-90.
[J Virol. 2007]J Virol. 2001 Jun; 75(11):5398-404.
[J Virol. 2001]PLoS Pathog. 2007 Oct 5; 3(10):1374-9.
[PLoS Pathog. 2007]Arch Virol. 1988; 103(1-2):117-26.
[Arch Virol. 1988]J Virol. 2008 Aug; 82(16):8059-70.
[J Virol. 2008]J Virol. 2005 Dec; 79(24):15511-24.
[J Virol. 2005]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4620-4.
[Proc Natl Acad Sci U S A. 2004]J Virol. 2007 May; 81(10):5181-91.
[J Virol. 2007]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4620-4.
[Proc Natl Acad Sci U S A. 2004]J Virol. 2007 May; 81(10):5181-91.
[J Virol. 2007]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]J Virol. 2002 Jun; 76(11):5654-66.
[J Virol. 2002]Am Rev Respir Dis. 1966 Mar; 93(3):Suppl:162-77.
[Am Rev Respir Dis. 1966]J Virol. 2005 Sep; 79(18):11788-800.
[J Virol. 2005]J Virol. 2008 Mar; 82(6):2741-51.
[J Virol. 2008]J Virol. 2008 Nov; 82(22):11294-307.
[J Virol. 2008]Nature. 1977 Dec 15; 270(5638):617-8.
[Nature. 1977]J Virol. 2001 Jun; 75(11):5410-5.
[J Virol. 2001]J Virol. 2001 Jun; 75(11):5398-404.
[J Virol. 2001]PLoS Pathog. 2007 Oct 5; 3(10):1374-9.
[PLoS Pathog. 2007]J Virol. 1998 Sep; 72(9):7626-31.
[J Virol. 1998]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4620-4.
[Proc Natl Acad Sci U S A. 2004]Virology. 1997 Jun 23; 233(1):224-34.
[Virology. 1997]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]J Virol. 2001 Jun; 75(11):5398-404.
[J Virol. 2001]PLoS Pathog. 2007 Oct 5; 3(10):1374-9.
[PLoS Pathog. 2007]PLoS Pathog. 2009 Jan; 5(1):e1000252.
[PLoS Pathog. 2009]J Virol. 2008 Aug; 82(16):8059-70.
[J Virol. 2008]J Virol. 2008 Sep; 82(18):8965-77.
[J Virol. 2008]Arch Virol. 1988; 103(1-2):117-26.
[Arch Virol. 1988]Virology. 2007 May 10; 361(2):384-90.
[Virology. 2007]J Virol. 2007 May; 81(10):5181-91.
[J Virol. 2007]J Virol. 2007 Jul; 81(13):6890-8.
[J Virol. 2007]J Virol. 2006 Aug; 80(15):7469-80.
[J Virol. 2006]J Virol. 2004 Nov; 78(22):12665-7.
[J Virol. 2004]Biochim Biophys Acta. 1957 Mar; 23(3):645-6.
[Biochim Biophys Acta. 1957]J Virol. 2004 Dec; 78(24):13755-68.
[J Virol. 2004]J Virol. 2008 Aug; 82(16):8059-70.
[J Virol. 2008]J Virol. 2008 Sep; 82(18):8965-77.
[J Virol. 2008]Emerg Infect Dis. 2005 Jul; 11(7):1036-41.
[Emerg Infect Dis. 2005]J Virol. 1998 Jul; 72(7):6014-23.
[J Virol. 1998]J Antimicrob Chemother. 2004 May; 53(5):759-65.
[J Antimicrob Chemother. 2004]Virology. 2004 Mar 30; 321(1):144-53.
[Virology. 2004]Proc Natl Acad Sci U S A. 1999 Aug 3; 96(16):9345-50.
[Proc Natl Acad Sci U S A. 1999]Virology. 1994 Nov 15; 205(1):17-23.
[Virology. 1994]J Virol. 1998 Sep; 72(9):7626-31.
[J Virol. 1998]J Virol. 2006 Aug; 80(16):8060-8.
[J Virol. 2006]Virology. 2004 Mar 30; 321(1):144-53.
[Virology. 2004]Appl Microbiol. 1968 Apr; 16(4):588-94.
[Appl Microbiol. 1968]